What China Pharma does

China Pharma Holdings, Inc. (NYSE American: CPHI) is a specialty pharmaceutical company that develops, manufactures, and markets branded generic pharmaceutical products, traditional Chinese medicines, and consumer health supplements. Founded in 1993 and headquartered in Haikou, Hainan Province, the company operates through its wholly-owned subsidiary Hainan Helpson Medical & Biotechnology Co., Ltd (海南惠普森医药生物技术有限公司). Manufacturing is conducted at two GMP-certified facilities in Haikou: a Phase I plant (approximately 8,000 m², built 2004) handling oral dosage forms, and a Phase II plant (approximately 40,000 m², built 2014) with new-version GMP-certified lyophilized powder injection and aqueous injection production lines, with surplus capacity offered for contract manufacturing.

The company's product portfolio spans five categories: anti-infective and respiratory drugs (cefaclor, cephalexin, roxithromycin, clarithromycin); central nervous system and cardio-cerebrovascular treatments (candesartan, cerebroprotein hydrolysate, gastrodin, ozagrel); digestive system drugs (tiopronin, omeprazole, hepatocyte growth-promoting factor); protective products and sanitizers (medical and KN95 masks, hand sanitizer); and a "Greater Health" consumer line including ARARATO-branded Noni enzyme and freeze-dried instant bird's nest supplements. The company distributes through a direct sales force reaching hospitals, clinics, and pharmacies across more than 30 Chinese provinces, complemented by a direct-to-consumer e-commerce storefront for health supplements. New drug R&D is focused on proprietary IP for cardiovascular, central nervous system, and anti-infective indications, supplemented by clinical research partnerships with over 20 Chinese research institutes, laboratories, and hospitals.

The business model is split between prescription pharmaceutical sales (cardiovascular, CNS, anti-infective, digestive categories) through hospital and pharmacy channels, consumer health supplements through e-commerce and retail, technology transfer and patent licensing transactions, and contract manufacturing services using excess GMP capacity. The company has been recognized as a National High-Tech Enterprise on five occasions (2001, 2006, 2010, 2013, 2016). Recent capital activity in 2026 includes a stock-funded $8.82 million patent acquisition in February and a $5 million registered direct offering in July that triggered a roughly 70% decline in the share price, alongside a December 2025 shareholder authorization for a reverse stock split of up to 1-for-20.

Name

China Pharma

Legal name

海南惠普森医药生物技术有限公司

Website

https://chinapharmaholdings.com

Company type

Public

Founded year

1993

Operating status

Operating

Headcount range

251–500 employees

Short description

China Pharma Holdings (NYSE American: CPHI) is a Haikou, Hainan-based specialty pharmaceutical manufacturer producing branded generic drugs across anti-infective, CNS/cardiovascular, and digestive categories, plus consumer health supplements, distributing to hospitals, pharmacies, and consumers across 30+ Chinese provinces.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210), Medicinal and Botanical Manufacturing (325411)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

Keywords

• Generic pharmaceuticals
• Pharmaceutical manufacturing
• Drug formulation
• Health supplements
• GMP manufacturing

Headquarters

HQ city

Hainan

HQ country

China

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Prescription Pharmaceuticals: The company generates revenue primarily from manufacturing and selling prescription pharmaceutical products including cardiovascular drugs, CNS medications, anti-infectives, and digestive treatments to hospitals and pharmacies.
2. Health and Wellness Products: Revenue from health supplements including Noni enzyme (ARARATO brand) and freeze-dried instant bird's nest products sold through e-commerce and retail channels.
3. Technology Transfer and Licensing: Acquisition of patents through stock issuance, such as the Topiroxostat Nanoemulsion patent from Xiaoyun Chen for $8.82 million via 12.6 million restricted shares.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels1 record

Core offering

China Pharma Holdings, Inc., through its operating subsidiary Hainan Helpson Medical & Biotechnology Co., Ltd, is a specialty pharmaceutical manufacturer that develops, produces, and sells branded generic drugs across five therapeutic categories — anti-infective and respiratory, central nervous system and cardio-cerebrovascular, digestive, medical protection (masks and sanitizers), and Greater Health consumer supplements (Noni enzyme, freeze-dried bird's nest). The company operates its own GMP-certified manufacturing facilities in Haikou, Hainan, and distributes prescription products through hospitals, clinics, and pharmacies across 30+ Chinese provinces while selling wellness supplements through direct e-commerce.

Product overview

China Pharma Holdings, Inc. (Hainan Helpson Medical & Biotechnology Co., Ltd.) is a specialty pharmaceutical company established in 1993, engaged in the development, manufacturing, and sale of branded generic drugs and health products. The company operates a diversified product portfolio organized into five therapeutic categories: (1) Anti-infective & Respiratory (anti-infectives, cold/flu medications) including Cefaclor Dispersible Tablets (希诺), Cephalexin Capsules, Roxithromycin Dispersible Tablets (倍沙), Clarithromycin Capsules (福可星), Naproxen Sodium Pseudoephedrine Sustained-Release Tablets (普森欧克), and Andrographolide Tablets; (2) Central Nervous System & Cardio-cerebrovascular including Candesartan Cilexetil Tablets, Cerebroprotein Hydrolysate Injection, Gastrodin Injection (疏畅), Ozagrel Sodium for Injection, Propylgallate for Injection, Alginic Sodium Diester Injection, and Bumetanide for Injection; (3) Digestive System including Tiopronin Enteric-Coated Capsules (普森力泰), Omeprazole Sodium for Injection, Compound Ammonium Glycyrrhetate S for Injection, and Hepatocyte Growth-Promoting Substance for Injection; (4) Protection & Wellness (PPE and sanitization products) including Medical Surgical Masks, KN95 Masks, Disposable Medical Masks, Disposable Protective Masks, and 75% Alcohol Hand Sanitizer; and (5) Greater Health Consumer Products (大健康) including Noni Enzyme (阿诺丽诺/ARARATO) and Freeze-Dried Instant Bird's Nest (至瑧品燕). The company's new drug R&D focuses on developing innovative drugs with proprietary intellectual property for cardiovascular diseases, central nervous system disorders, and anti-infective applications. Manufacturing operations are conducted at GMP-certified facilities in Haikou, Hainan Province, including a Phase I plant (8,000 m2, built 2004) and a Phase II plant (40,000 m2, built 2014).

Differentiator

Problem solved

Functional benefit

Brands

• ARARATO: Premium Noni enzyme health supplement brand, utilizing locally sourced Noni fruit from Hainan Island. Positioned as a high-quality dietary supplement under the company's Big Health division.
• 普森力泰
• 惠普森
• 希诺
• 普森欧克
• 福可星
• 倍沙
• 疏畅
• 阿诺丽诺
• 至瑧品燕
• 申能凯

Products and services

• Cefaclor Dispersible Tablets (头孢克洛分散片) / 希诺 (XINUO) Cephalosporin antibiotic dispersible tablets indicated for respiratory infections including pneumonia, bronchitis, tonsillitis, and urinary tract, skin, soft tissue, and biliary infections caused by sensitive bacteria. Targeted at hospitals, pharmacies, and patients with respiratory infections. Awarded Hainan Province Pharmaceutical Industry Excellent Product Brand Award in 2016.
• Cephalexin Capsules (头孢氨苄胶囊) Cephalosporin antibiotic capsules indicated for acute tonsillitis, pharyngitis, otitis media, sinusitis, bronchitis, pneumonia, urinary tract infections, and skin and soft tissue infections caused by sensitive organisms. For hospital, pharmacy, and patient use.
• Andrographolide Tablets (穿心莲内酯片) Traditional Chinese medicine tablet with heat-clearing, detoxifying, and anti-inflammatory properties, indicated for upper respiratory tract infections and bacterial dysentery. Distributed through hospital and pharmacy channels.
• Roxithromycin Dispersible Tablets (罗红霉素分散片) / 倍沙 (BEISHA) Macrolide antibiotic dispersible tablet indicated for pharyngitis, tonsillitis, sinusitis, otitis media, bronchitis, pneumonia, urethritis, and skin infections. For hospital, pharmacy, and patient use.
• Naproxen Sodium Pseudoephedrine Sustained-Release Tablets (萘普生钠伪麻黄碱缓释片) / 普森欧克 (PUSENOUKE) Compound cold medication combining naproxen sodium and pseudoephedrine hydrochloride in a 12-hour sustained-release formulation for relief of nasal congestion, runny nose, headache, fever, sore throat, and muscle pain without drowsiness. For pharmacy and consumer use.
• Clarithromycin Capsules (克拉霉素胶囊) / 福可星 (FUKEKONG) Macrolide antibiotic capsule indicated for upper and lower respiratory tract infections, skin and soft tissue infections, otitis media, mycoplasma pneumonia, chlamydial infections, Legionella, MAC infections, and H. pylori eradication. For hospital and pharmacy distribution.
• Candesartan Cilexetil Tablets (坎地沙坦酯片) Angiotensin II receptor blocker for the treatment of primary hypertension; can be used alone or in combination with other antihypertensive drugs; provides organ protection for the heart, kidneys, and blood vessels. For hospital and pharmacy distribution.
• Cerebroprotein Hydrolysate Injection (脑蛋白水解物注射液) Brain-specific peptide neurotrophic drug extracted from pig brain tissue, used to improve memory and attention deficit symptoms in patients with traumatic brain injury and cerebrovascular disease (cerebral insufficiency, cerebral infarction) sequelae. For hospital use.
• Gastrodin Injection (天麻素注射液) / 疏畅 (SHUCHANG) Injection for treatment of neurasthenia, neurasthenia syndrome, and vascular neurological headaches (migraine, trigeminal neuralgia), as well as vestibular disorders including Meniere's disease, traumatic vertigo, and sudden deafness. For hospital use.
• Alginic Sodium Diester Injection (藻酸双酯钠注射液) Polysaccharide compound extracted from seaweed, indicated for ischemic cardiovascular and cerebrovascular diseases (cerebral thrombosis, cerebral embolism, coronary heart disease) and hyperlipidemia; reduces blood viscosity and improves microcirculation. For hospital use.
• Ozagrel Sodium for Injection (注射用奥扎格雷钠) Thromboxane A2 synthase inhibitor (National Medical Insurance Catalog) that inhibits platelet aggregation, dissolves thrombi, dilates cerebral blood vessels, increases blood flow, and prevents cerebrovascular spasm; used for acute thrombotic cerebral infarction and associated movement disorders. For hospital use.
• Propylgallate for Injection (注射用棓丙酯) Injection for the prevention and treatment of cerebral thrombosis, coronary heart disease, and postoperative thrombotic deep vein phlebitis; inhibits platelet aggregation induced by thromboxane A2 and reduces blood viscosity. For hospital use.
• Bumetanide for Injection (注射用布美他尼) Loop diuretic for the treatment of various edema conditions (heart failure, cirrhosis, nephritis, renal failure), hypertension, acute renal failure prevention, hyperkalemia, hypercalcemia, and acute drug poisoning rescue. For hospital use.
• Tiopronin Enteric-Coated Capsules (硫普罗宁肠溶胶囊) / 普森力泰 (PUSENLITAI) Enteric-coated hepatoprotective capsule for acute and chronic hepatitis B and drug-induced liver injury; protects the liver, promotes repair, provides comprehensive detoxification, and resists damage. For hospital and pharmacy use.
• Omeprazole Sodium for Injection (注射用奥美拉唑钠) Proton pump inhibitor injection for gastroesophageal reflux disease, gastric ulcers, recurrent duodenal ulcers, and Zollinger-Ellison syndrome when oral therapy is not applicable; also for acute gastric mucosal injury and prevention/treatment of upper gastrointestinal bleeding. For hospital use.
• Hepatocyte Growth-Promoting Substance for Injection (注射用促肝细胞生长素) Small-molecule peptide active substance extracted and purified from fresh pig liver; used as adjunctive treatment for various severe viral hepatitis (acute, subacute, and chronic severe hepatitis in early or mid-stage). For hospital use.
• Compound Ammonium Glycyrrhetate S for Injection (注射用复方甘草酸单铵S) Compound injection for acute and chronic hepatitis-related liver dysfunction, toxic/traumatic hepatitis and liver cancer as adjunctive therapy, and food/drug poisoning and drug allergies. For hospital use.
• Metronidazole Tablets (甲硝唑片) / 惠普森 (HUIPUSEN) Antiparasitic and antibacterial tablet for treatment of intestinal and extraintestinal amoebiasis, trichomoniasis, giardiasis, cutaneous leishmaniasis, and dracunculiasis; also widely used for anaerobic bacterial infections. For hospital and pharmacy distribution.
• Granisetron Hydrochloride Injection (盐酸格拉司琼注射液) Antiemetic injection for the prevention of nausea and vomiting induced by radiotherapy and chemotherapy during malignant tumor treatment. For hospital use.
• Vitamin B6 for Injection (注射用维生素B6) / 申能凯 (SHENNENGKAI) Vitamin supplement injection for the prevention and treatment of Vitamin B6 deficiency, isoniazid poisoning, pregnancy/cancer drug-induced vomiting, and pellagra; also for total parenteral nutrition and increased Vitamin B6 requirements. For hospital use.
• Medical Surgical Masks (医用外科口罩) / 惠普森 (HUIPUSEN) Three-layer non-woven medical surgical face mask with bacterial filtration efficiency (BFE) >= 95%, sterile, designed for clinical personnel during invasive procedures to protect against pathogens, body fluids, and particles. Produced under GMP pharmaceutical factory conditions.
• KN95 Particulate Protective Masks (KN95颗粒物防护口罩) KN95 respirator mask for protection against particles generated during grinding, sanding, sweeping, sawing, and bagging operations, as well as metal fumes from welding and brazing.
• Disposable Medical Masks (一次性使用医用口罩) Three-layer non-woven disposable medical mask with BFE >= 95% and ventilation resistance <= 49 Pa/cm2, for clinical personnel during non-invasive procedures.
• Disposable Protective Masks (一次性防护口罩) Three-layer filtering disposable protective mask produced in a 100,000-class dust-free workshop under GMP pharmaceutical factory conditions; for daily life protection against particulate matter and pollutants.
• 75% Alcohol Hand Sanitizer (75%酒精免洗消毒液) 75% alcohol no-rinse hand sanitizer spray for hand and surface disinfection; effective against E. coli, Staphylococcus aureus, and Candida albicans; produced in a pharmaceutical factory.
• Noni Enzyme / Noni Juice (诺丽酵素) / 阿诺丽诺 (ARARATO) Noni fruit (Morinda citrifolia) based health supplement; Noni is rich in xeronine and xeronine-converting enzymes; a natural, nutritious dietary supplement produced in a GMP-certified facility using locally sourced Hainan Noni fruit. Available in 500ml family pack and 50ml gift pack. For direct-to-consumer e-commerce sales.
• Freeze-Dried Instant Bird's Nest (冻干即冲燕窝) / 至臻品燕 (ZHI ZHEN PIN YAN) Freeze-dried instant bird's nest product for health supplement; reconstituted by mixing with warm water. Sold through direct-to-consumer e-commerce as a premium wellness product.

Segments1 record

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Two partnerships are on record, tiered core.

• 20+ Research Institutes, Independent Laboratories, and Hospital Clinical Research PartnerscoreStrategic or Co-development PartnerStrategic R&D partnerships with over 20 leading Chinese research institutes, independent laboratories, and hospitals for clinical research cooperation to advance drug development and biomedical research.
• Xiaoyun ChencoreStrategic or Co-development PartnerTechnology transfer agreement for acquisition of Topiroxostat Nanoemulsion invention patent for $8.82 million via 12.6 million restricted shares of common stock.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Regional players

• Lotus Pharmaceuticals: Asian specialty pharmaceutical company focused on generic drugs and health supplements — comparable as a small-cap specialty pharma manufacturer with branded generics and consumer health products, though primarily Taiwan/Southeast Asia focused rather than mainland China.
• Hainan Haiyao Co., Ltd. Hainan Province-based Chinese pharmaceutical manufacturer with a portfolio of generic injectables, oral solids and APIs serving domestic hospital channels — directly comparable as a regional Hainan-based Chinese generic pharma peer of similar scale and operating geography.

Direct peers

• Tianjin Tasly Pharmaceutical: Chinese pharmaceutical company combining traditional Chinese medicine botanicals (notably danshen-based cardiovascular products) with Western generics, distributed through hospital and pharmacy channels — comparable in the Western-Chinese medicine hybrid approach and cardiovascular therapeutic focus.
• China Traditional Chinese Medicine Holdings: Hong Kong-listed Chinese pharmaceutical manufacturer combining Western-style generics with traditional Chinese medicine products in cardiovascular, digestive and respiratory areas — directly comparable in therapeutic areas and the hybrid Western/TCM product strategy employed by China Pharma.
• Livzon Pharmaceutical Group: Chinese pharmaceutical manufacturer with diversified prescription drug portfolio including digestive, anti-infective, cardiovascular and CNS products, distributed through hospital and pharmacy channels — closely comparable in therapeutic category mix and domestic China go-to-market model.

Broad incumbents

• Sino Biopharmaceutical Limited: Hong Kong-listed major Chinese pharmaceutical group with broad prescription drug portfolio covering cardiovascular, hepatobiliary, oncology and respiratory therapeutics — directly comparable as a multi-therapeutic Chinese prescription pharma manufacturer competing in the same hospital channels.
• CSPC Pharmaceutical Group: Large Hong Kong-listed Chinese pharmaceutical manufacturer with diversified generic and innovative drug portfolio across cardiovascular, CNS, anti-infective and other therapeutic categories — comparable as a broad Chinese pharma competitor in overlapping therapeutic areas, though substantially larger and more R&D-intensive.
• China Resources Pharmaceutical Group: Large state-owned Chinese pharmaceutical manufacturer and distributor with broad therapeutic portfolio and hospital-channel distribution — comparable as a competing manufacturer-distributor of generic and branded prescription drugs into China's hospital channel.
• Shanghai Pharmaceuticals Holding: State-backed Chinese pharmaceutical manufacturer and distributor with nationwide hospital and pharmacy distribution network and diversified prescription drug portfolio — directly comparable in the prescription pharma plus distribution model, though at a vastly larger scale.

Emerging players

• Hutchison China MediTech (HUTCHMED): China-focused pharmaceutical and consumer health company with prescription drug pipeline plus consumer health products distributed in China — comparable in the prescription-plus-consumer-health dual structure, though HUTCHMED is substantially more R&D-intensive and oncology-focused.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/china-pharma-holdings-inc

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries1 record

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about China Pharma